EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat
